UNITED STATES FOOD & DRUG ADMINISTRATION

Financial Disclosure by Clinical Investigators

OMB Control Number 0910-0396

*Terms of Clearance: None.*

SUPPORTING STATEMENT – Part A: Justification

1. Circumstances Making the Collection of Information Necessary

This information collection implements Food and Drug Administration (FDA, us or we) regulations. FDA regulations in 21 CFR Part 54 require the sponsor of any drug, including a biological product, or device marketing application (applicant), to submit certain information concerning the compensation to, and financial interests of, any clinical investigator conducting certain clinical studies. This requirement applies to any covered clinical study of a drug or device submitted in a marketing application that the applicant or FDA relies on to establish that the product is effective, including studies that show equivalence to an effective product, or that make a significant contribution to the demonstration of safety. The regulations require applicants to certify to the absence of certain financial interests of clinical investigators and/or disclose those financial interests, as required, when covered clinical studies are submitted to FDA in support of product marketing. The regulations are intended to ensure that financial interests and arrangements of clinical investigators that could affect reliability of data submitted to FDA in support of product marketing are identified and disclosed by the sponsor of any drug, biological product, or device marketing application. If the applicant does not include certification or disclosure, or both, if required, or does not certify that it was not possible to obtain the information, the agency may refuse to file the application.

The information collection includes the following:

21 CFR 54.4(a) - Reporting by Sponsors of Product Marketing Applications; Certification (Form FDA 3454) or Disclosure (Form FDA 3455) (Reporting)

The sponsor of an application submitted under sections 505, 506, 510(k), 513, or 515 of the Federal Food Drug, and Cosmetic Act (FD&C Act), or section 351 of the Public Health Service Act, that relies in whole or in part on clinical studies, shall submit for each clinical investigator who participated in a covered clinical study either a certification as described in § 54.4(a)(1) and (a)(2), or a disclosure statement as described in § 54.4(a)(3).

The applicant covered by this section shall submit for all clinical investigators (as defined in § 54.2(d)) to whom the certification applies, a completed Form FDA 3454 attesting to the absence of financial interest and arrangements described in § 54.4(a)(3).

For any clinical investigator defined in § 54.2(d), for whom the applicant does not submit the certification described in § 54.4(a)(1) and (a)(2), the applicant shall submit a completed Form FDA 3455 disclosing completely and accurately the following: Any financial arrangements, any significant payments, any proprietary interest, any significant equity interest, and any steps taken to minimize the potential for a bias resulting from any of the disclosed arrangement, interest, or payments.

21 CFR 54.4(b) - Certification and Disclosure Requirements (Third-Party Disclosure)

Clinical investigators subject to investigational new drug application (IND) or investigational device exemption (IDE) regulations must provide the sponsor of the study with sufficient accurate information needed to allow subsequent disclosure or certification.

21 CFR 54.6 - Recordkeeping and Record Retention

A sponsor who has submitted a marketing application containing covered clinical studies shall keep on file certain information pertaining to the financial interests of clinical investigators.

We therefore request OMB approval of the information collection associated with financial disclosure of clinical investigator requirements found in the applicable regulations, as discussed in this supporting statement, and found in the referenced collection instruments.

2. Purpose and Use of the Information Collection

The information to be collected from sponsors of product marketing applications will be submitted to FDA as part of the marketing applications, using Form FDA 3454 and Form FDA 3455. For each clinical investigator who took part in a covered clinical study, the sponsor will either certify that the investigator has no financial interest or arrangement identified in § 54.4(a)(3), or will disclose identified interests and arrangements held by the clinical investigator and describe steps taken to minimize potential bias of such interests and arrangements on the clinical study results. Clinical investigators will provide sponsors with sufficient accurate information to enable the sponsor to submit certification and disclosure statements. Certification of a clinical investigator helps to assure FDA reviewers of the integrity of a clinical study. Disclosure of an identified interest or arrangement and steps taken to minimize potential bias is used by reviewers to evaluate whether the integrity of the study may be relied on. When identified interests or arrangements are disclosed, FDA responds in one of the following ways: If the clinical study in which the investigator participated was well designed and managed, FDA may accept the data without further question. If a clinical investigator’s financial interests and arrangements raise serious questions about the integrity of the data and the study design does not include sufficient bias-minimizing steps to offset these questions, FDA initiates audits of the data by reviewers, requests further analyses of the data from the sponsor, requests that the sponsor conduct additional studies to confirm the potentially biased study, or refuses to treat data from the study as pivotal or primary data upon which an agency action can be taken. Under currently applicable product review regulations, reviewers can and do request further analyses of data from a sponsor as appropriate, or request that a sponsor conduct additional studies to confirm the results of a questionable study.

3. Use of Improved Information Technology and Burden Reduction

Sponsors may electronically maintain and make available records in accordance with the requirements in § 54.6. FDA will also accept electronic submissions, such as are required under § 54.5(a) to the extent allowed by the agency’s capability for automated data processing of marketing applications. FDA is working to improve this capability, with the goal of eventually accepting electronically all submissions related to product review.

4. Efforts to Identify Duplication and Use of Similar Information

In drafting the regulation, FDA consulted with the Public Health Service (PHS) and National Science Foundation (NSF), which have issued respectively a regulation and a policy statement on financial disclosure by scientific investigators. It should be noted that the PHS and NSF documents respond to principles that govern federally funded grants and contracts. Such funds are granted for all types of research, and these organizations must guard against bias in all types of research. In contrast, FDA must rely on clinical data in making safety and effectiveness determinations for regulated products, and FDA’s primary interest is in clinical data. There is potential for the FDA and PHS regulations to overlap in a very small number of instances involving PHS-funded clinical research on FDA-regulated products. In the preamble to the proposed regulation, FDA asked for public comment on whether, in such instances, meeting the PHS requirement for disclosure should be considered to meet FDA’s requirement. Based on comments received and further deliberation, FDA has concluded that FDA’s reporting requirements meet different needs for the most part and the information submitted in the PHS and NSF formats does not overlap and is not adequate for product review purposes.

Because there is currently no other FDA mechanism for collecting the information that is required under the FDA regulation, there is no internal duplication.

5. Impact on Small Businesses or Other Small Entities

FDA has conducted a Regulatory Flexibility Analysis of this regulation and concludes that it will not have a significant impact on a substantial number of small businesses. This is the case because in developing the regulation FDA has kept in mind that, not only are the majority of firms that submit marketing applications to FDA of a size to be considered small businesses by the Small Business Administration, but also the firms most apt to be affected by the disclosure provisions of the regulation are small entities of two types: (1) firms whose owners are likely to have developed the tested product and who serve as clinical investigators and (2) small start-up firms that are not heavily capitalized and provide clinical investigators with equity interests as reimbursement. FDA has addressed the need to minimize burden in a number of ways. The regulation does not prohibit any financial interest, such as compensation to investigators in the form of equity in the sponsors firm, nor is the agency proposing to require divestiture by the investigator of any financial interest, because such provisions could impact significantly on small entities and hinder their ability to bring innovative products to market. The reporting and recordkeeping burdens are the minimum necessary to achieve the goals of the proposed regulation.

Submission of the required information has been made as simple as possible for small entities. FDA has developed forms for certification and disclosure, and a sponsor may submit one form for all clinical investigators for whom certification is being made.

6. Consequences of Collecting the Information Less Frequently

The required information is to be submitted as part of a product marketing application, which amounts to a one-time collection. The concept of less frequent collection is not applicable.

Without the information that is required by this regulation, FDA lacks the means to evaluate whether clinical data submitted in support of the safety and effectiveness of a regulated product are vulnerable to a recognized source of potential bias, and to assure that the public health is not threatened with the consequences of biased data.

7. Special Circumstances Relating to the Guidelines of 5 CFR 1320.5

There is one special circumstance relating to the guidelines of 5 CFR 1320.5: The records required to be kept under § 54.6 would be retained by sponsors for 2 years after the date of approval of the application. As such, records will be generated at the outset of a clinical trial; it is conceivable that they would be kept by sponsors for more than 3 years. Two years after the date of approval of the application is the normal period of time for retention of all other information related to an application.

8. Comments in Response to the Federal Register Notice and Efforts to Consult Outside the Agency

In accordance with 5 CFR 1320.8(d), FDA published a 60-day notice for public comment in the FEDERAL REGISTER of December 2, 2021 (86 FR 68500). FDA received one comment, however, it was not responsive to the four collection of information topics solicited and therefore this comment will not be discussed in this document.

9. Explanation of Any Payment or Gift to Respondents

There will not be any payment or gift to respondents.

10. Assurance of Confidentiality Provided to Respondents

This ICR collects personally identifiable information (PII). Form 3454 (Certification: Financial Interests and Arrangements of Clinical Investigators) collects name and signature. Form 3455 (Disclosure: Financial Interests and Arrangements of Clinical Investigators) collects name, signature, and an attachment with detailed information about financial interests and arrangements. PII is collected in the context of the subject individuals’ professional capacity and the FDA-related work they perform for their employer (e.g., point of contact at a regulated entity).

FDA has made no guarantee of confidentiality to sponsors or clinical investigators, but will keep disclosed information private to the fullest extent allowed by law. Information provided to, or obtained by, FDA is subject to release under the Freedom of Information Act (5 U.S.C. 552) and the implementing regulations contained in 21 CFR Parts 20 and 21.

FDA further determined that although PII is collected the collection is not subject to the Privacy Act of 1974 and the particular notice and other requirements of the Act do not apply. Specifically, FDA does not use name or any other personal identifier to routinely retrieve records from the information collected via submitted Forms 3454 and 3455 or otherwise in relation to this collection.

FDA also minimized the PII to be collected to protect the privacy of the individuals. To ensure against the solicitation or submission of unnecessary PII, FDA designed the forms to provide fields soliciting only information required to meet the intended purpose behind the forms.

11. Justification for Sensitive Questions

The information collection does not include questions that are of a sensitive nature, such as, sexual behavior and attitudes, religious beliefs, and other matters that are commonly considered private.

1. Estimates of AnnualizedBurden Hours and Costs

12a. Annualized Hour Burden Estimate

Respondents to this collection are sponsors of marketing applications that contain clinical data from studies covered by the regulations. These sponsors represent pharmaceutical, biologic, and medical device firms. Respondents are also clinical investigators who provide financial information to the sponsors of marketing applications. Applicants already submit in a marketing application a complete list of clinical investigators for each covered study (BLAs, 21 CFR part 601, are covered under OMB control number 0910-0338; PMAs, 21 CFR part 814, are covered under OMB control number 0910-0231; 510(k)s, 21 CFR part 807 subpart E, are covered under OMB control number 0910-0120; NDAs and ANDAs, 21 CFR part 314, are covered under OMB control number 0910-0001).

Table 1 shows information that is the basis of the estimated number of respondents in Tables 2 through 4:

| Table 1.--Estimated Number of Applications, Clinical Trials, and Investigators Subject to the Regulation by Type of Application1 | | | | |
| --- | --- | --- | --- | --- |
| Application Type | Total Number of Applications | Number of Applications Affected | Number of Trials | Number of Investigators |
| Drugs:  New drug application (NDA), new molecular entity (NME)  NDA non-NME  NDA efficacy supplement  Abbreviated new drug application (ANDA)  ANDA supplement  CBER2 Biologics:  Biologics license application (BLA)  BLA efficacy supplement  CDER3 Biologics:  BLAs  BLA efficacy supplements  Medical Devices:  Premarket approval (PMA)  PMA supplement  Reclassification devices  510(k)  De Novo requests | 55  78  196  821  10,894  10  30  25  102  39  29  0  3,947  63 | 55  37  119  1  1  10  30  25  65  39  29  0  247  57 | 3 to 10  3 to 10  1 to 3  1.1  1  3 to 10  1 to 3  3 to 10  1 to 3  1 to 3  1 to 3  0  1  1 to 3 | 3 to 100  3 to 100  10 to 30  2  2  3 to 100  10 to 30  3 to 100  10 to 30  10 to 20  3 to 10  0  3 to 10  10 to 20 |
| 1 Source: Agency estimates  2 Center for Biologics Evaluation and Research (CBER)  3 Center for Drug Evaluation and Research (CDER) | | | | |

Reporting Burden:

For clinical investigators not employed by the applicant and/or the sponsor of the covered study, the applicant must either certify to the absence of certain financial arrangements with clinical investigators or disclose those arrangements to FDA. FDA estimates that almost all applicants submit a certification statement under § 54.4(a)(1) and (a)(2). Preparation of the statement using Form FDA 3454 should require no more than 1 hour per study. The number of respondents is based on the estimated number of affected applications (see table 1 above).

When certification is not possible and disclosure is made using form FDA 3455, the applicant must describe, under § 54.4(a)(3), the financial arrangements or interests and the steps that were taken to minimize the potential for bias in the affected study. As the applicant would be fully aware of those arrangements and the steps taken to address them, describing them will be straightforward. The agency estimates that it will take about 5 hours to prepare this narrative. Based on our experience with this collection, FDA estimates that approximately 10 percent of the respondents with affected applications will submit disclosure statements.

| Table 2.--Estimated Annual Reporting Burden | | | | | |
| --- | --- | --- | --- | --- | --- |
| 21 CFR Section | No. of Respondents | No. of Responses per Respondent | Total Annual Responses | Average Burden per Response | Total Hours |
| Certification--54.4(a)(1) and (a)(2)--Form FDA 3454 | 715 | 1 | 715 | 1 | 715 |
| Disclosure--54.4(a)(3)--Form FDA 3455 | 72 | 1 | 72 | 5 | 360 |
| Total | | | | | 1,075 |

Recordkeeping Burden:

The sponsors of covered studies are required to maintain complete records of compensation agreements with any compensation paid to nonemployee clinical investigators, including information showing any financial interests held by the clinical investigator, for 2 years after the date of approval of the applications. This time is consistent with the current recordkeeping requirements for other information related to marketing applications for human drugs, biologics, and medical devices. Under § 54.6, sponsors of covered studies must maintain many records regarding clinical investigators, including protocol agreements and investigator resumes or curriculum vitae. FDA estimates that it takes an average of 15 minutes for each recordkeeper to add this record to their file.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Table 3.--Estimated Annual Recordkeeping Burden | | | | | |
| 21 CFR Section | No of Recordkeepers | No. of Records per Recordkeeper | Total Annual Records | Average Burden per Recordkeeping | Total Hours1 |
| Recordkeeping--54.6 | 715 | 1 | 715 | 0.25 | 179 |
| 1 Numbers have been rounded. | | | | | |

Third-Party Disclosure Burden:

Under §54.4(b), clinical investigators must provide sponsors of the covered studies with sufficient accurate information to make the required disclosure or certification. Because much of the information required can be obtained from the applicant's own records, the costs incurred by the clinical investigator will be minimal. Clinical investigators are required to do one of two things: (1) Provide a statement that they, their spouse, and their dependent children did not have a significant equity interest as defined in § 54.2(b) in the sponsor of the covered study, or (2) disclose any such interest. Clinical investigators are accustomed to supplying such information in even greater detail when applying for research grants. Most people know the financial holdings of their immediate family, and records of such interests are generally accessible because they are needed for preparing tax records. FDA estimates that the time required for this task may range from 5 to 15 minutes; we used the mean, 10 minutes, for the average burden per disclosure. The number of respondents is the sum of the number of affected applications multiplied by the mean of the estimated number of investigators for each application type (rounded) in table 1 above.

| Table 4.--Estimated Annual Third-Party Disclosure Burden | | | | | |
| --- | --- | --- | --- | --- | --- |
| 21 CFR Section | No. of Respondents | No. of Disclosures per Respondent | Total Annual Disclosures | Average Burden per Disclosure | Total Hours1 |
| 54.4(b)--Clinical Investigators | 13,082 | 1 | 13,082 | 0.17 | 2,224 |
| 1 Numbers have been rounded. | | | | | |

12b. Annualized Cost Burden Estimate\*

*Reporting (certification and disclosure)*: FDA estimates that virtually all of the sponsors submitting marketing applications that contain clinical data (approximately 715) will be able to certify for one or more investigators, and the names of all investigators for whom the sponsor is certifying may be attached to one certification form. The agency estimates that preparation of the certification form will take at most 1 hour, of which 80% is clerical time ($16.67/hr.) and 20% management time ($54.54/hr.). We then doubled to account for benefits and overhead, providing a weighted wage rate of $47.58/hr. The agency bases this estimate on sampling of time taken in preparation of other portions of marketing applications. The total estimated time spent by sponsors of marketing applications on certification in a given year is estimated to be 715 hours.

The agency estimates that preparation of the disclosure form, which includes identifying the interest or arrangement held by the investigator and describing steps taken to minimize bias of study results, will take 5 hours, of which 90% is management time ($54.54/hr.) and 10% clerical time ($16.67/hr.). We then doubled to account for benefits and overhead, providing a weighted wage rate of $109.08/hr. The total estimated time spent by sponsors of marketing applications on disclosure in a given year is estimated to be 360 hours.

*Recordkeeping*: As stated, recordkeeping requires minimal time because a sponsor can incorporate financial disclosure information into the sponsors existing system for maintaining investigator information. It is estimated that an average of 15 minutes is needed for inclusion of this information in an application record. In calculating the cost of recordkeeping, the same weighted wage rate is used as for certification: $47.58/hr.

*Third-party disclosure*: Clinical investigators report to sponsors, in whose studies they participate, sufficient, accurate information to enable the sponsor to complete certification and disclosure forms. Most clinical investigators will have no disclosable information to report to the sponsor, and for these investigators reporting will amount to checking a box or writing the equivalent of disclosable financial arrangements. Even if an investigator holds disclosable interests or arrangements, most of this information will already be known by the sponsor, i.e., a financial arrangement between the sponsor and the clinical investigator whereby the value of the compensation to the investigator could be influenced by the outcome of the study; any significant payments of other sorts to the clinical investigator by the sponsor; any proprietary interest in the tested product held by the clinical investigator; and, if the sponsor is not a publicly held corporation, any significant equity interest in the sponsor that is held by the investigator. The investigator will need only provide the sponsor with information concerning a significant equity interest in the sponsor, providing the sponsor is publicly held. Because the investigator will have such information readily available for tax purposes, FDA estimates that only minimal time will be spent by the investigator in providing this information to the sponsor. FDA believes the average time spent by a clinical investigator in providing a sponsor with the required financial information will be 10 minutes (0.17 hours). Approximately 13,082 clinical investigators participate in covered clinical studies in a given year. Thus, a total of 2,224 burden hours is estimated for reporting by clinical investigators to sponsors in a given year. Cost of this burden is calculated using a physician’s mean hourly wage ($119.65), doubled to account for benefits and overhead, $239.30.

| Annualized Cost Burden Estimate | | | |
| --- | --- | --- | --- |
|  | Hours | Hourly Wage Rate | Cost (rounded) |
| Sponsors’ costs: | | | |
| Certification | 715 | $47.58 | $34,020 |
| Disclosure | 360 | $109.08 | $39,269 |
| Recordkeeping | 179 | $47.58 | $8,517 |
| Sponsors’ total costs: | | | $81,806 |
| Clinical Investigators’ costs: | | | |
| Third-party disclosure | 2,224 | $239.30 | $532,203 |
| Total costs to sponsors and investigators: | | | $614,009 |

\* Wage rate calculations are based on: Bureau of Labor and Statistics May 2020 data (<http://www.bls.gov/oes/current/naics4_561100.htm#00-0000>) for “Office Clerks, General” (occupation code 43-9061); “Managers, All Others” (occupation code 11-9198); and “Physicians and Surgeons, All Other” (occupation code 29-1228).

13. Estimates of Other Total Annual Costs to Respondents and/or Recordkeepers/Capital Costs

There are no additional information collection costs to respondents and recordkeepers beyond those estimated in the previous item. This is because the information will be collected and submitted as part of preparation of a marketing application, and sponsors already have in place processes and equipment for collecting and maintaining information from clinical investigators who study FDA-regulated products. Investigators who participate in clinical studies of regulated products provide sponsors of the studies with a variety of information and are thus accustomed to this activity.

14. Annualized Cost to the Federal Government

Because FDA already has in place equipment and processes for handling information contained in product marketing applications, the information collected under this regulation will generate new costs to the agency in only two areas:

(1) Additional review of applications to assure that the required information has been submitted and all clinical investigators participating in covered studies are accounted for. Agency staff estimates that this review could take from 15 to 20 minutes for an application in which all clinical investigators are certified to upwards of 5 hours for an application that includes disclosure for an investigator. For planning purposes, an average of 2 hours is estimated for this review. The initial review and assessment of applications would be conducted by a Consumer Safety Officer.

(2) Agency data audit of a covered clinical study. If a clinical investigators financial interests and arrangements raise serious questions about the integrity of the data, and the study design does not include sufficient bias-minimizing steps to offset these questions, one course of action FDA can take is to request a data audit by agency bioresearch monitoring staff. FDA estimates that 10 percent of sponsors of marketing applications will submit disclosures for clinical investigators in a given year. The agency estimates that only a very few would contain financial interests and arrangements that raise questions about the integrity of the data that are sufficiently serious, and study design sufficiently questionable, to trigger a data audit. For planning purposes, the agency has set this figure at one-half of one percent of submitted applications, or 5 applications. A data audit may cover a wide range of time, based on the size and complexity of a study and the number of investigators participating, but 40 hours is a realistic average time for such an audit.

The hourly rate is based on the Food and Drug Administration fully loaded FTE cost model (domestic) for the Center for Devices and Radiological Health for FY 2021 ($270,305), as provided by agency economists, and calculated for a 40-hour work week.

| Estimated Annual Costs to FDA | | | | |
| --- | --- | --- | --- | --- |
|  | Hours per Review | Average Hourly Rate | No. of Applications | Cost |
| Additional review | 2 | $129.95 | 715 | $185,829 |
| Data audit | 40 | $129.95 | 5 | $25,990 |
| Total | | | | $211,819 |

15. Explanation for Program Changes or Adjustments

Our estimated burden for the information collection reflects an overall increase of 298 hours and a corresponding increase of 4,485 responses/records. We attribute this adjustment to an increase in the number of affected applications and the number of investigators. The estimated number of respondents has decreased from 1,050 to 715 for Certification, from 105 to 72 for Disclosure, and from 1,050 to 715 for Recordkeeping due to a decrease in the estimated number of affected applications. The estimated number of respondents for third-party disclosure has increased from 7,894 to 13,082 due to adjustments in the number of affected applications and the number of investigators. No program changes were made. Upon review, we have corrected an inadvertent omission with regard to the number of biologics license applications (BLAs) and BLA efficacy supplements received by our Center for Drug Evaluation and Research (CDER) and used, in part, as a basis for calculating the cumulative burden estimate. We have corrected that error here, as reflected in table 1.

16. Plans for Tabulation and Publication and Project Time Schedule

Results of this information collection will not be published.

17. Reason(s) Display of OMB Expiration Date is Inappropriate

FDA will display the OMB expiration date as required by 5 CFR 1320.5.

18. Exceptions to Certification for Paperwork Reduction Act Submissions

There are no exceptions to the certification.